Valuation: Ocular Therapeutix, Inc.

Market Cap 2.23B 1.95B 1.8B 1.66B 3.16B 213B 3.21B 21.53B 8.45B 105B 8.39B 8.2B 361B P/E 2026 *
-6.37x
P/E 2027 * -7.24x
Enterprise Value 1.87B 1.64B 1.51B 1.39B 2.64B 178B 2.69B 18.03B 7.08B 87.88B 7.02B 6.87B 302B EV / Sales 2026 *
36x
EV / Sales 2027 * 18.4x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-3.23%
1 week+5.81%
Current month+3.87%
1 month+17.24%
3 months+16.04%
6 months-9.41%
Current year-15.98%
1 week 9.42
Extreme 9.425
10.94
1 month 8.62
Extreme 8.62
10.94
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 2024-04-14
Director of Finance/CFO 50 2026-01-19
Chief Tech/Sci/R&D Officer - 2021-09-27
Director TitleAgeSince
Director/Board Member 71 2023-07-09
Director/Board Member 78 2012-11-04
Director/Board Member 70 2021-09-19
Date Insider Type Main position Quantity % Market Cap.
06-15Don

Chief Executive Officer

-100,184 0.0473%
06-09Free

Director

58,000 0.0274%
06-09Free

Director

58,000 0.0274%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%+5.81%-7.52%+110.31% 2.23B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.38%-2.34%+23.30%+62.06% 357.61B
Weighted average by Cap. -1.32%-2.95%+36.72%+83.92%

Financials

2026 *2027 *
Net sales 51.91M 45.41M 41.88M 38.68M 73.4M 4.95B 74.63M 500M 197M 2.44B 195M 191M 8.38B 120M 105M 97.13M 89.71M 170M 11.48B 173M 1.16B 456M 5.66B 452M 442M 19.44B
Net income -362M -316M -292M -270M -511M -34.5B -520M -3.49B -1.37B -17B -1.36B -1.33B -58.43B -331M -289M -267M -246M -467M -31.53B -475M -3.19B -1.25B -15.53B -1.24B -1.21B -53.39B
Net Debt -363M -318M -293M -270M -513M -34.62B -522M -3.5B -1.37B -17.06B -1.36B -1.33B -58.63B -18M -15.74M -14.52M -13.41M -25.45M -1.72B -25.88M -174M -68.14M -846M -67.58M -66.11M -2.91B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
26-07-10 US$10.20 -3.23% 1,875,628
26-07-09 US$10.54 +2.63% 2,429,217
26-07-08 US$10.27 -0.58% 3,201,097
26-07-07 US$10.33 +6.94% 2,873,909
26-07-06 US$9.660 +0.21% 2,407,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.20USD
Average target price
27.09USD
Spread / Average Target
+165.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock